TopicalDosed ingredientTherapeutic flag Cosmetic cross-reference

Tafluprost

CAS 209860-87-7

Tafluprost (CAS 209860-87-7) is a Phase 4 pharmaceutical compound with 1 bioactivity target and 112 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
2
SOURCE DrugCentral
Adverse signals
112
SOURCE IUPHAR/BPS
PubMed IDs
1
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Tafluprost
CAS Number
209860-87-7
UNII
1O6WQ6T7G3
InChIKey
WSNODXPBBALQOF-VEJSHDCNSA-N
ChEMBL ID
CHEMBL1963683
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
dosed ingredienttherapeutic flagtopical
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL1963683 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE EMBL-EBI ChEMBL 2 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- AC50 29342.68064516129 nM 31 -
Prostaglandin F2-alpha receptor
GPCR
 AGONIST - - Homo sapiens
SOURCE DrugCentral 18 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Ocular hyperaemia 83 328.172 10030041
Eye irritation 61 235.386 10015946
Eye pain 53 167.895 10015958
Eye pruritus 39 136.851 10052140
Intraocular pressure increased 22 81.534 10022806
Eye swelling 23 63.298 10015967
Lacrimation increased 18 47.455 10023644
Photophobia 17 44.256 10034960
Eyelid irritation 8 43.788 10057385
Atrioventricular block second degree 12 42.323 10003677
Erythema of eyelid 10 41.948 10015237
Vision blurred 26 39.441 10047513
Pemphigoid 13 37.776 10034277
Foreign body sensation in eyes 9 37.65 10051116
Cardiovascular insufficiency 9 36.796 10065929
No adverse event 19 33.404 10067482
Eyelids pruritus 7 32.969 10051627
Product storage error 14 32.649 10079843

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE IUPHAR/BPS 1 interaction

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

TargetAction AffinityPubMed
FP receptor
PTGFR
 Agonist - 15037111
SOURCE NLM RxNorm 3 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
TAFLUPROST 1244607 SU MTHSPL
Tafluprost 1244607 SU MTHSPL
tafluprost 1244607 IN RXNORM
SOURCE SIDER 72 side-effect rows

Side Effects

SIDER side-effect terms mapped to the drug or same-CAS compound identity.

Side EffectDrug Name MedDRA TypeConcept ID
Asthma tafluprost PT C0004096
Blepharal pigmentation tafluprost LLT C0854438
Blepharal pigmentation tafluprost PT C0854438
Cataract tafluprost LLT C0086543
Cataract tafluprost PT C0086543
Common cold tafluprost LLT C0009443
Conjunctival hyperaemia tafluprost LLT C1761613
Conjunctival hyperaemia tafluprost PT C1761613
Conjunctivitis allergic tafluprost LLT C0009766
Conjunctivitis allergic tafluprost PT C0009766
Cough tafluprost LLT C0010200
Cough tafluprost PT C0010200
Dry eye tafluprost LLT C0314719
Dry eye tafluprost PT C0314719
Dyspnoea tafluprost LLT C0013404
Dyspnoea tafluprost PT C0013404
Endophthalmitis tafluprost PT C0014236
Erythema of eyelid tafluprost LLT C0239454
Erythema of eyelid tafluprost PT C0239454
Exacerbation of asthma tafluprost LLT C0349790
Eye discharge tafluprost LLT C0423006
Eye discharge tafluprost PT C0423006
Eye disorder tafluprost LLT C0015397
Eye disorder tafluprost PT C0015397
Eye irritation tafluprost LLT C0235266
Eye irritation tafluprost PT C0235266
Eye pain tafluprost LLT C0151827
Eye pain tafluprost PT C0151827
Eye pain tafluprost PT C0151827
Eye pruritus tafluprost LLT C0022281
Eye pruritus tafluprost PT C0022281
Eyelash darkening tafluprost LLT C1536146
Eyelash discolouration tafluprost LLT C1142111
Eyelash discolouration tafluprost PT C1142111
Eyelash hyperpigmentation tafluprost PT C1536145
Eyelash thickening tafluprost LLT C1142112
Eyelash thickening tafluprost PT C1142112
Eyelid oedema tafluprost LLT C0162285
Eyelid oedema tafluprost PT C0162285
Foreign body sensation in eyes tafluprost LLT C0920171
Foreign body sensation in eyes tafluprost PT C0920171
Growth of eyelashes tafluprost LLT C0423847
Growth of eyelashes tafluprost PT C0423847
Headache tafluprost LLT C0018681
Headache tafluprost PT C0018681
Iris hyperpigmentation tafluprost LLT C0877306
Iris hyperpigmentation tafluprost PT C0877306
Iritis tafluprost LLT C0022081
Iritis tafluprost PT C0022081
Lacrimation increased tafluprost LLT C0152227
Lacrimation increased tafluprost PT C0152227
Nasopharyngitis tafluprost PT C0027441
Nervous system disorder tafluprost LLT C0027765
Nervous system disorder tafluprost PT C0027765
Ocular hyperaemia tafluprost LLT C0155169
Ocular hyperaemia tafluprost PT C0155169
Ocular stinging tafluprost LLT C0863079
Photophobia tafluprost LLT C0085636
Photophobia tafluprost PT C0085636
Pruritus tafluprost LLT C0033774
Pruritus tafluprost PT C0033774
Punctate keratitis tafluprost LLT C0259799
Punctate keratitis tafluprost PT C0259799
Rhinitis tafluprost PT C0035455
Urinary tract infection tafluprost LLT C0042029
Urinary tract infection tafluprost PT C0042029
Uveitis tafluprost LLT C0042164
Uveitis tafluprost PT C0042164
Vision blurred tafluprost LLT C0344232
Vision blurred tafluprost PT C0344232
Visual acuity reduced tafluprost LLT C0234632
Visual acuity reduced tafluprost PT C0234632
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Tafluprost used for in pharmaceutical contexts?

Tafluprost (CAS 209860-87-7) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Tafluprost?

Tafluprost has 112 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Ocular hyperaemia, Eye irritation, Eye pain, Eye pruritus, Intraocular pressure increased. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Tafluprost also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Tafluprost with EU status "permitted".

What clinical phase is Tafluprost in?

Tafluprost is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Tafluprost?

Tafluprost has 2 bioactivity rows in this page query. Rendered target entries include Prostaglandin F2-alpha receptor.